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Abstract
Background: Overall, Indigenous Australians with cancer are diagnosed with more advanced disease, receive less
cancer treatment and have poorer cancer survival than non-Indigenous Australians. The prognosis for Indigenous
people with specific cancers varies however, and their prognosis for cancers of the head and neck is largely
unknown. We therefore have compared clinical characteristics, treatment and survival between Indigenous and
non-Indigenous people diagnosed with head and neck cancer in Queensland, Australia.
Methods: Rates were based on a cohort of Indigenous people (n = 67), treated in public hospitals between 1998
and 2004 and frequency-matched on age and location to non-Indigenous cases (n = 62) also treated in the public
health system. Data were obtained from hospital records and the National Death Index. We used Pearson’s Chi-
squared analysis to compare categorical data (proportions) and Cox proportional hazard models to assess survival
differences.
Results: There were no significant differences in socioeconomic status, stage at diagnosis or number and severity
of comorbidities between Indigenous and non-Indigenous patients, although Indigenous patients were more likely
to have diabetes. Indigenous people were significantly less likely to receive any cancer treatment (75% vs. 95%, P =
0.005) and, when cancer stage, socioeconomic status, comorbidities and cancer treatment were taken into account,
they experienced greater risk of death from head and neck cancer (HR 1.88, 1.10, 3.22) and from all other causes
(HR 5.83, 95% CI 1.09, 31.04).
Conclusion: These findings show for the first time that Indigenous Australians with head and neck cancer receive
less cancer treatment and suggest survival disparity could be reduced if treatment uptake was improved. There is a
need for a greater understanding of the reasons for such treatment and survival disparities, including the impact of
the poorer overall health on cancer outcomes for Indigenous Australians.
Background
Overall, Indigenous Australians with cancer are diag-
nosed with more advanced disease, receive less cancer
treatment and have poorer cancer survival than non-
Indigenous Australians [1,2]. However, the prognosis for
Indigenous people with specific cancers such as those of
the head and neck is largely unknown.
The term “cancers of the head and neck” refers to a
group of cancers that occur on the lip, tongue, gum,
oral cavity, the sinuses, nose, salivary glands and throat
[3]. Most head and neck tumours are squamous cell car-
cinomas (SCC) for which significant risk factors include
smoking and alcohol exposure, and increasingly, infec-
tion by human papillomavirus (HPV), which now
reportedly accounts for 25% of cases in the United
States [4]. Head and neck cancers rank as the fifth most
commonly occurring cancer type for Australia overall
[5] and also for Indigenous people in Queensland [6].
Little is known about the incidence and mortality of
head and neck cancer among Indigenous relative to
non-Indigenous populations in the developed world.
Overall incidence of oral and pharyngeal cancers
amongst American Indians/Alaskan Natives (AI/AN)
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was reportedly lower than for whites but varied widely
across districts of the United States, and stage distribu-
tion was found to be less favourable for AI/AN [7]. In
the Indigenous population of the Northern Territory of
Australia, the incidence of head and neck cancer is
around 32.78 per 100,000 compared to 19.5 per 100,000
for the rest of Australia [8] and higher incidence and
mortality from cancer of the oropharynx have previously
been reported in the Northern Territory Indigenous
population when compared to non-Indigenous people
[2]. Whilst incidence was reportedly similar among Indi-
genous and non-Indigenous people with head and neck
cancers in Queensland between 1997 and 2006, mortal-
ity was more than three times greater for Indigenous
people [6].
It is not known to what extent established prognostic
factors such as late stage at diagnosis, the presence and
severity of comorbidities or differences in cancer treat-
ment account for the excess mortality among Indigen-
ous Australians with head and neck cancer. Therefore
we conducted this population-based study to compare
these factors and survival between Indigenous and non-
Indigenous Australians diagnosed with this disease.
Methods
Subjects
The study was conducted in Queensland, the north-
eastern state of Australia, which has a population of 4.5
million, 3.6% of whom identify as Aboriginal, Torres
Strait Islander, or both (respectfully referred to here as
Indigenous) [9]. All Indigenous people (over 18 years)
residing in Queensland and diagnosed with head and
neck cancer between 1998 and 2004 were identified
through the population-based Queensland Cancer Regis-
try (QCR). To improve the efficiency of this cohort
study, Indigenous patients were matched to a random
sample of 74 non-Indigenous people with incident head
and neck cancer also identified through the Cancer Reg-
istry, of corresponding age (within +/- 5 yrs), sex and
location of residence (in terms of degree of remoteness
from a major centre).
Clinical data were abstracted from the records at 14
public hospitals to a standard form by one of the research-
ers (SPM), an experienced nurse, and a former Registrar
of the Queensland Cancer Registry. Where records were
insufficient, further data were extracted from secondary
public hospitals’ records. Records were reviewed for diag-
nostic details such as date, histology and method of diag-
nosis, cancer stage, treatment and presence of
comorbidities. Cancer staging was documented by treating
doctors as either Tumour, Nodes and Metastasis (TNM)
scores, American Joint Committee on Cancer Staging
Scores (I - IV) [10] or as localised cancer, regional spread
or metastatic disease; for comparability, TNM and AJCC
scores were converted to localised/regional/distant spread
using commonly accepted cut- points.
Treatment type, including surgery, radiotherapy and
chemotherapy were recorded, as was treatment intention
(any intent, curative intent or intention not known).
Date, duration and quantity of treatment were also col-
lected. The presence or absence of comorbid conditions
was recorded, and a modified Charlson Comorbidity
Index Score (referred to here as ‘comorbidity score’) was
assigned (based on severity and number of comorbid
conditions and were grouped thus: No score, 1, 2-5 and
5+). Specifically, diabetes, cardio and cerebrovascular
disease, hypertension, respiratory illness, renal disease,
history of previous cancer and other serious comorbid-
ities that were accepted in the Charslon Comorbidity
Scoring framework, were assessed [11]. A Socioeco-
nomic score was assigned using the Socio-Economic
Index For Areas (SEIFA) index (based on geographical
areas of residence ranked into quintiles: 1 representing
the most disadvantaged, and 5 the most advantaged)
[12]. Date and cause of death were obtained from the
Australian National Death Index.
Statistical methods
Pearson’s Chi-squared analysis or Fisher’s Exact test were
used for categorical data (proportions), t-test for normally-
distributed data (means), and non-parametric tests (Krus-
kal-Wallis Test) for non-normally-distributed data (med-
ians). Crude and adjusted survival analyses were
conducted using Cox proportional hazard models. Hazard
ratios were adjusted for stage of cancer at diagnosis, pre-
sence and severity of comorbidities, socioeconomic status
and ‘any’ or ‘curative’ cancer treatment and treatment
mode, defined as any curative surgery, radiotherapy or
chemotherapy or combination of these. The reference
category was “non-Indigenous” unless otherwise stated.
All analyses were calculated using Statistics Package for
the Social Sciences (PASW) for Windows version 17.0.
Ethical approval to conduct the study was obtained
from the Queensland Health Department, all hospitals
where data collection took place, and the Queensland
Institute of Medical Research. An Indigenous Reference
Group was established to inform the study investigators
about cultural matters and the translation of results to
the community.
Results
Demographics and Clinical features
As all Indigenous patients had attended a Queensland
public hospital, two non-Indigenous patients who were
primarily treated in a private facility were excluded. In
addition, cases with cancer of the lip, which mostly
arises on the sun-exposed non-mucosal epithelium in
white-skinned people [13], were excluded as 7 of the 8
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cancers of the lip in the study occurred in the non-Indi-
genous cohort. Medical records were not available for
two Indigenous and three non-Indigenous patients, leav-
ing 67 Indigenous and 62 non-Indigenous people with
head and neck cancers for study.
Mean age was 56 years for Indigenous and 55 years for
non-Indigenous people and there was no difference in
the proportion of males and females, degree of remote-
ness from a major centre or socioeconomic index
between the two groups (Table 1). The percentages of
Indigenous and non-Indigenous patients with squamous
cell carcinoma were similar (Indigenous 96% vs. non-
Indigenous 90%). There was no significant difference in
stage at diagnosis (Table 1): the majority of people were
diagnosed with regional spread of their cancer (Indigen-
ous 57%, non-Indigenous 65%) and no Indigenous or
non-Indigenous people from urban regions were diag-
nosed with a late stage cancer. There was little difference
in the comorbidity score between Indigenous and non-
Indigenous people (Table 1) and although a greater pro-
portion of Indigenous people had diabetes (12% vs. 3%),
this difference was not statistically significant (P = 0.09).
Indigenous people with cancer of the head and neck were
significantly less likely to receive any cancer treatment
(either palliative treatment, treatment with curative intent
or treatment with intention unknown) than their non-Indi-
genous counterparts (75% vs. 95%, P = 0.005). Furthermore,
when people with metastatic cancer or uncertain stage were
excluded, Indigenous patients were less likely to receive
treatment with curative intent (48% vs. 76%, P = 0.002)
(Table 2). Compared to non-Indigenous patients, the pat-
tern of curative treatment received by Indigenous patients
was significantly different (P = 0.03). The most common
modes of treatment for Indigenous patients were surgery
only (36%) or surgery and radiotherapy (25%) compared to
surgery and radiotherapy (40%) and chemotherapy (30%)
for their non-Indigenous counterparts (Table 2).
The characteristics of those who did not receive treat-
ment were examined more closely. Indigenous people
aged over 60 were less likely to receive any treatment
than non-Indigenous people of similar age (40% did not
receive treatment compared to 5%), as were Indigenous
men when compared to non-Indigenous men (30% vs.
5%). Indigenous people with regional spread of disease
(27% vs. 5%), those from urban, rural and remote areas
and those from all socioeconomic strata, were also less
likely to receive any treatment than their non-Indigen-
ous counterparts. The comorbidity score was similar for
Indigenous people and non-Indigenous people who did
not receive treatment. When only cases with non-meta-
static disease were compared, older Indigenous people
(42% vs. 31%), those from the most accessible areas
(26% vs. 8%), those from the most remote areas (32% vs.
15%), and the most socially disadvantaged (55% vs. 31%)
were less likely to receive treatment with curative intent
than their non-Indigenous counterparts. 46% of Indigen-
ous people with a comorbidity score of zero did not
receive treatment compared to 68% of non-Indigenous
people with the same score but the numbers were too
small to show significance (data not shown).
The pattern of curative treatment received by Indigen-
ous patients without metastatic disease was significantly
different from that of non-Indigenous patients (Table 2).
However there were no significant differences in time to
surgery or radiotherapy for those who received cancer
treatment and Indigenous people were as likely to com-
plete radiotherapy and received a similar course of
radiotherapy as their non-Indigenous counterparts.
Survival
There was no statistically significant difference between
the groups regarding recurrence recorded in the medical
chart (Table 2). The pattern of death was significantly
different when Indigenous patients were compared to
non-Indigenous patient; 79% of Indigenous patients were
deceased by the end of the follow up period compared to
52% of non-Indigenous patients (Table 2) with risk of all
cause-specific death doubled for Indigenous people (HR
2.19 95% CI 1.36, 3.53) (Table 3). When time to cancer
death was adjusted for cancer stage, the hazard ratio was
2.45 (95% CI 1.51, 3.96), with little variation when further
adjusted for socioeconomic status and comorbidities.
When further adjusted for overall treatment, the differ-
ence was less but remained statistically significant (HR
1.88% CI 1.10, 3.22). However, when curative treatment
and mode of treatment were taken into account, the sur-
vival difference was no longer evident (Table 3).
Indigenous patients were also more likely to die of
causes other than cancer when compared to non-Indi-
genous patients (n = 9 (17%) vs. n = 3, (9%)), though the
difference was not statistically significant (Table 2).
When we compared time to death from other causes
between the two groups (Table 3), we found head and
neck cancer Indigenous patients to be 7 times more likely
than non-Indigenous patients to die of causes other than
the cancer after diagnosis (HR, unadjusted, 7.33 95% CI
1.52, 35.18, P = 0.01) and this was largely unaffected
when adjusted separately for cancer stage, presence and
severity of comorbidities and diabetes (data not shown),
or after adjustment for any cancer treatment (fully
adjusted HR 5.83 95% CI 1.09, 31.04, P = 0.039).
Discussion
This study reports clinical characteristics, treatment and
survival for 67 Indigenous people diagnosed with head
and neck cancer between 1998 and 2004 in Queensland,
Australia. As the number of cases was small, and the
data collection restricted to information available from
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Table 1 Demographic and clinical details, for Indigenous and non-Indigenous patients with cancer of the head and
neck in Queensland Australia, 1998- 2004







Cancer site (ICD code)
Floor of Mouth (C04) 5 (8) 7 (11)
Gum (C03) 1 (2) 3 (5)
Hypopharynx (C13) 1 (2) 2 (3)
Lip, oral cavity, pharynx - ill defined (C14) 9 (13) 6 (10)
Nasopharynx (C11) 3 (5) 2(3)
Oropharynx (C10) 5 (8) 2 (3) 0.26
Palate (C05) 8 (12) 2 (3)
Parotid (C07) 3 (5) 7 (11)
Pyriform Sinus (C12) 7 (10) 7 (11)
Tongue (C01- C02) 15 (22) 20 (32)
Tonsil ( C09) 5 (8) 4 (7)
Unspecified Salivary glands (C08) 1 (2) 0
Unspecified mouth (C06) 4 (6) 0
Age
18- 39 2 (3) 4 (7)
40-59 40 (60) 39 (63) 0.52
60+ 25 (37) 19 (30)
Sex
Male 47 (70) 43 (70) 0.92
Female 20 (30) 19 (30)
Area of remoteness (ARIA)
Highly accessible 11 (17) 7 (11)
Accessible 9 (14) 10 (16) 0.28
Moderately accessible 25 (37) 33 (53)
Remote 9 (13) 6 (10)
Very remote 13 (19) 6 (10)
Socioeconomic status (SEIFA )
1 Most disadvantaged 26 (39) 13 (21)
2 Low to Intermediate advantage 13 (19) 20 (32)
3 Intermediate advantage 13 (19) 13 (21) 0.19
4 Advantaged 11 (16) 12 (19)
5 Most advantaged 4 (6) 2 (3)
9 Not known 0 2 (3)
Stage at diagnosis (SEER score)
Localised cancer 23 (34) 15 (24)
Regional Spread 38 (57) 40 (65) 0.41
Distant metastasis 5 (7) 7 (11)
Not sure 1 (2) 0
Charlson Comorbidity Index (Scores grouped)
0 42 (63) 42 (68)
1 16 (24) 8 (13) 0.30
2- 5 9 (13) 11 (18)
5+ 0 1 (2)
Specific comorbidities
Diabetes
No 59 (88) 60 (97) 0.09
Yes 8 (12) 2 (3)
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medical records, the study is largely descriptive in nat-
ure and limited in interpretive power. As a result of
matching, Indigenous and non-Indigenous people with
head and neck cancer in this study shared a similar
demographic profile for location of residence, age and
sex, and all attended Queensland public hospitals. We
found that only 7% of Indigenous and 11% of non-
Indigenous patients were diagnosed with metastatic dis-
ease, in keeping with reports that advanced stage at
diagnosis is relatively uncommon for head and neck
cancer [14].
Overall, Indigenous people with head and neck cancer
were less likely to receive any cancer treatment and when
only cases with non-metastatic disease were compared,
the treatment disparity was even greater. How this com-
pares with other Indigenous populations with head and
neck cancer is not known as no similar published data are
available. However, treatment bias among Indigenous peo-
ple with cancer in general, and with other specific cancers,
has been reported in a number of studies [1,15-17]. The
reasons why Indigenous people in this study were less
likely to receive treatment are not precisely known but we
found that those Indigenous people who do not receive
treatment were likely to be older, male and socially disad-
vantaged compared to non-Indigenous people who did
not receive treatment. Indigenous people were also less
Table 1 Demographic and clinical details, for Indigenous and non-Indigenous patients with cancer of the head and
neck in Queensland Australia, 1998- 2004 (Continued)
Hypertension
No 55 (82) 47 (76) 0.39
Yes 12 (18) 15 (24)
Circulatory disease*
No 61 (91) 51 (82) 0.19
Yes 6 (9) 11 (18)
*Cardiovascular or cerebrovascular disease
Table 2 Comparison of cancer treatment given,












Treatment 50 (75) 59 (95)
No Treatment 15 (22) 3 (5) 0.005
Not sure 2 (3) 0
Curative treatment given * N = 59 N = 53
Curative treatment 28 (48) 40 (76) 0.002
No curative treatment 31 (52) 13 (24)
Mode of curative treatment *
Surgery only 10(36) 4 (10)
Chemotherapy only 1 (4) 0
Radiotherapy only 5 (18) 4 (10) 0.03




Chemoradiotherapy 5 (18) 12 (30)
Recurrence N = 67 N = 62
Recurrence recorded 13 (19) 14 (23)
No recurrence 49 (73) 45 (72) 0.77
Not enough information 5 (8) 3 (5)
Time from diagnosis to death
Alive at 31st Dec 2006 14 (21) 30 (48)
Deceased in < 3 months 14 (21) 4 (7)
Deceased 3 month to 12 months 21 (31) 10 (16) 0.003
Deceased 12 months to 2 years 11 (17) 8 (13)
Deceased greater than 2 years 7 (10) 10 (16)
Cause of death N = 53 N = 32
Cancer death 44 (83) 29 (91) 0.33
Non cancer death 9 (17) 3 (9)
*Metastatic cases excluded
Table 3 Proportional hazard ratios, using Cox regression
models, of time to death for head and neck cancer
patients diagnosed between 1998 and 2004, for
Indigenous people in Queensland (reference category is
last for all variables)
HR (95% CI)
Crude Time to all-cause death 2.50 (1.59, 3.93)
Crude Time to cancer-specific death: 2.19 (1.36, 3.53)
Adjusted for: Stage^ 2.45 (1.51, 3.96)
Stage, SEIFA^^ 2.41 (1.47, 3.93)
Stage, SEIFA, CCI score # 2.35 (1.42, 3.78)
Stage, SEIFA, diabetes 2.34 (1.42, 3.85)
Stage, SEIFA, CCI score, any treatment 1.88 (1.10, 3.22)
Stage, SEIFA, CCI score, curative treatment 1.59 (0.92, 2.73)
Stage, SEIFA, CCI score, mode of treatment## 1.50 (0.86, 2.64)
Crude Time to non-cancer death 7.33 (1.52, 35.1)
Adjusted for: any treatment 5.83 (1.09, 31.04)
^ Stage: 1 = localised, 2 = regional spread, 3 = distant metastasis, 4 = not
known
^^ SEIFA: 1 = Most disadvantaged, 2 = Mod disadvantage, 3 = Most
Advantaged
# Charlson Comorbidity Index (CCI) score: 1 = 0, 2 = 1, 3 = 2-5, 4 = 5+
## Modes of treatment: 0 = No Treatment 1 = surgery, 2 = chemotherapy
only, 3 = radiotherapy only, 4 = surgery and radiotherapy, 5 = surgery,
chemotherapy and radiotherapy, 6 = chemoradiation
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likely to receive curative treatment than their non-Indi-
genous counterparts.
A number of barriers to the use of cancer and other
health services for Indigenous Australians have been iden-
tified in the literature, and include lack of proximity, avail-
ability and cultural appropriateness of health services, lack
of specialist care, transport, health insurance and health
services affordability, as well as inadequate proficiency in
English [16,18-20]. In general these details were not avail-
able from the medical records, and are therefore not
assessed in this study. Reports suggest factors such as late
stage at diagnosis [17], greater prevalence of comorbidities
[1] and disparate treatment decisions made by health pro-
fessionals based on assumptions about socioeconomic and
cultural factors [21] may explain some of the treatment
differential, but reports are not conclusive.
There was no significant difference in cancer stage or
comorbidities between Indigenous and non-Indigenous
patients in the present study that might account for the
treatment differential, and although we are confident that
the medical records were a reliable source of information
on cancer stage and the most important comorbidities
such as those included in the Charlson index (e.g. diabetes,
cardiovascular disease), we acknowledge that our study
was small and consequently had limited power to detect
small differences between the groups with certainty; con-
sequently some differences may not have been detected.
However, it is well known that there is a greater overall
burden of comorbidities among the Australian Indigenous
population in general and in those with cancer [1,15] and
given that Indigenous head and neck cancer patients in
this study were 7 times more likely to die from causes
other than cancer than non-Indigenous patients, and
around 6 times more likely to die from other causes after
accounting for any cancer treatment received, it is plausi-
ble that chronic ill-health is associated with less treatment.
We acknowledge some possible under-representation of
Indigenous patients in this study due to misclassification
of Indigenous status at the QCR; however a data quality
audit of Queensland hospitals, who provide cancer notifi-
cation to the QCR, suggest a high level of accurate identi-
fication, so this is likely to be minimal [22]. We also
believe the Indigenous to non-Indigenous comparison to
be internally valid, with little, if any, misclassification of
Indigenous status in the study sample, as medical charts
were carefully reviewed to verify Indigenous status and
discrepant cases were excluded. Unfortunately smoking
history was not routinely available from the medical
records for this study and we were therefore unable to
investigate possible associations between smoking and
head and neck cancer for this population. As up to 40% of
Indigenous people are reported to smoke and smoking has
been strongly associated with head and neck cancer [23],
we recommend more thorough collection of smoking data
in the health records of Indigenous patients to enable bet-
ter assessment of the long-term impact on the health of
this population.
Indigenous people who did receive treatment were sig-
nificantly less likely to receive surgery with adjuvant
radiotherapy, the most commonly administered mode of
treatment for head and neck cancer in the early stages
[4]. However, as mode of treatment varies depending on
the tumour site and extent and, as the distribution of
cancer types differed somewhat among Indigenous and
non-Indigenous people in the present study, it was diffi-
cult to compare treatment modes between the two
groups. When those who had treatment were compared,
there was no difference in dose, duration or completion
rate of radiotherapy between Indigenous and non-Indi-
genous people with head and neck cancer and overall,
time to any treatment and curative treatment was also
similar. Although numbers were small, the implication
is that once engaged in treatment, the treatment path-
way was likely to be similar between Indigenous and
non-Indigenous people in the public setting in Queens-
land. This accords with a 2006 report by Condon and
colleagues who found that whilst Indigenous patients
were less likely to be recommended treatment, there
was no significant difference in completion [15].
When cancer-specific death was adjusted for socioeco-
nomic status, the presence and severity of comorbidities
and cancer stage, the survival difference remained the
same and changed little when adjusted for treatment.
However, when curative treatment and mode of treatment
were taken into account, the survival difference was no
longer significant. This might suggest that if the same
treatment was offered, Indigenous people would have
similar survival from head and neck cancer as non-Indi-
genous people. Although the numbers in our cohort were
small and so the results lacked statistical precision, we
identified disparities in cancer treatment delivery which
should be further investigated and addressed by health ser-
vice personnel. Although survival from head and neck
cancer in Indigenous populations has not been reported
elsewhere, the results of this study are consistent with the
poor cancer survival and worse mortality that has been
extensively reported for Indigenous people in Australian
with other cancers [24,25]. We were unable to adjust for
the presence of HPV which has been found to be a predic-
tor of survival in whites in America [26] as HPV testing
was not routinely undertaken at the time of the study.
Conclusions
Despite the small sample size, the study obtained statisti-
cally significant and clinically important differences in
treatment and survival in Indigenous people with head
and neck cancer in Queensland Australia. Indigenous peo-
ple treated in the public health system in Queensland
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were similar in socioeconomic status and stage of disease
to non-Indigenous people and received less treatment and
had poorer survival than non-Indigenous people with head
and neck cancer. Further study is needed to ascertain to
what extent the observed differences may be explained by
differences in the true burden of comorbidities in Indigen-
ous and non-Indigenous people.
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